RBC Capital raises Lam Research stock price target on strong demand

Lam Research reported fiscal Q3 2026 EPS of $1.47 versus $1.35 expected and revenue of $5.84 billion versus $5.73 billion consensus, while management lifted its 2026 wafer fabrication equipment outlook to $140 billion from $135 billion. RBC raised its price target to $310 from $290 and highlighted strong GenAI-driven demand, DRAM strength, improving NAND trends, and continued momentum into 2027. Multiple brokers also lifted targets after the beat and raised guidance, reinforcing a constructive outlook for the stock.

Analysis

The key read-through is that Lam is not just riding a cyclical upturn; it is seeing demand pull forward across the two segments that matter most for operating leverage: advanced logic/foundry and memory. That matters because when both are improving simultaneously, the earnings inflection is usually steeper than the revenue inflection, and suppliers with process-critical exposure tend to gain pricing power before the broader semi equipment basket re-rates.

The second-order effect is on the rest of the capital equipment chain: if Lam’s commentary is accurate, the constraint is shifting from customer caution to actual fab capacity and tool availability. That tends to benefit high-beta semi capex names with memory or leading-edge exposure, while lagging analog/legacy equipment suppliers can underperform if investors rotate into names with direct GenAI monetization. The market is likely underestimating how long this can persist if wafer fab equipment demand stays above the revised 2026 level into 2027, because that would support multiple years of order visibility rather than a single-year EPS beat.

The main risk is that the stock is already discounting a lot of the good news: at these levels, the setup is no longer about upside to estimates, but about whether the next guidance step-up is large enough to justify further multiple expansion. Any sign of China demand normalization, NAND delay, or capex digestion in memory could hit the stock hard over the next 1-2 quarters because the name is now owned as a quality growth proxy, not a value recovery trade.

The contrarian view is that the consensus may be overconfident in duration but underconfident in cyclicality. If GenAI-related capex shifts from broad buildout to optimization, Lam can still grow, but the market may compress the multiple before fundamentals break. That creates a good tactical setup to own the tape, but not necessarily to chase it aggressively after a near-52-week-high move.

Key Decisions for Investors

• Stay long LRCX on pullbacks over the next 2-6 weeks, but size modestly: the earnings/guidance trend supports momentum, while upside from here is more likely multiple-driven than estimate-driven.
• Buy LRCX Jan-2027 calls or call spreads to express the multi-year capex thesis; use defined risk because the stock is already near peak valuation and sentiment is crowded.
• Pair trade: long LRCX / short a weaker semi-capex laggard with less direct GenAI and memory leverage over 1-3 months; this isolates relative earnings revision upside from broader sector beta.
• If LRCX breaks below its post-earnings support on any China or NAND slowdown headline, fade quickly: the stock’s high ownership makes it vulnerable to a 10-15% air pocket on guidance disappointment.
• For conservative accounts, wait for a 5-8% reset before adding; the risk/reward is better on a digestion move than after an analyst-upgrade cluster near the highs.